Diabetic Retinopathy Market Global Analysis, Demand, Revenue, Statistics and Trend Analysis Research Report by 2027

                                      Diabetic Retinopathy Market

Diabetic retinopathy is a serious medical disorder that damages the eyes as a result of diabetes. Damage to the blood vessels of the light-sensitive tissue of the retina is the main cause of diabetic retinopathy. Blurred vision, fluctuating vision, black or empty spots in the vision, decreased colour vision, and vision loss are the most typical symptoms of this illness. A high sugar level in the blood causes blockage of the retina's small blood capillaries, limiting blood flow. Advanced instances of diabetic retinopathy require laser therapy or surgical operations. Mild-to-moderate cases of diabetic retinopathy can be cured with appropriate diabetes control; however, advanced cases require laser treatment or surgical procedures.

The Diabetic retinopathy market is driven by an increase in the prevalence of diabetes, a rise in the elderly population, an increase in the incidence of diabetes-related blindness, and a greater focus on early diagnosis to control illnesses. However, the shortage of qualified ophthalmologists and the long time it takes for medications to be approved are limiting this increase. During the projection period, however, the advent of combination treatments for the treatment of diabetic macular edoema, as well as expanding markets in Asia-Pacific and Latin America, are projected to create many prospects for market expansion.


Market Segmentation:

By Type

• Mild

• Moderate

• Severe

By Disease Form

• Proliferative diabetic retinopathy

• Non-proliferative diabetic retinopathy

By Management

• Anti-VEGF

• Intraocular steroid injection

• Laser surgery

• Vitrectomy

Chronic diseases such as cardiovascular disease, diabetes, and sleep problems are predicted to become more prevalent as the global elderly population grows. Patients over 65 years old with a history of diabetes are at a higher risk of developing proliferative diabetic retinopathy.


The key players operating in the global diabetic retinopathy market include Novartis AG, Regeneron Pharmaceuticals, Bayer Healthcare, Actavis Plc, Alimera Science, Pfizer Inc., Hoffmann-La Roche Ltd, Abbott Laboratories Ltd, Sirnaomics, Glycadia pharmaceuticals, Boehringer Ingelheim, Therapeutics Inc, Ampio pharmaceuticals, Lupin ltd, and others.